StockNews.com Begins Coverage on OpGen (NASDAQ:OPGN)

StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN) in a research report report published on Tuesday. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Stock Performance

Shares of NASDAQ:OPGN remained flat at $2.28 during trading on Tuesday. The stock had a trading volume of 2,100 shares, compared to its average volume of 81,880. OpGen has a 52 week low of $1.65 and a 52 week high of $38.40. The stock has a 50 day simple moving average of $2.68 and a two-hundred day simple moving average of $4.10.

OpGen (NASDAQ:OPGN) last issued its earnings results on Monday, July 8th. The medical research company reported $0.21 earnings per share for the quarter. The firm had revenue of $0.17 million for the quarter. OpGen had a negative return on equity of 1,827.76% and a negative net margin of 997.34%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in OpGen stock. Chase Investment Counsel Corp bought a new position in shares of OpGen, Inc. (NASDAQ:OPGN) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned approximately 2.63% of OpGen at the end of the most recent reporting period. 2.68% of the stock is owned by hedge funds and other institutional investors.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.